{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T17:17:17Z","timestamp":1776359837540,"version":"3.51.2"},"reference-count":194,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T00:00:00Z","timestamp":1674864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sao Paulo Research Foundation (FAPESP)","award":["25000.015000\/2019-53"],"award-info":[{"award-number":["25000.015000\/2019-53"]}]},{"name":"National Ministry of Health (Brazil)","award":["25000.015000\/2019-53"],"award-info":[{"award-number":["25000.015000\/2019-53"]}]},{"name":"Public Ministry of Labor Campinas (Research, Prevention, and Education of Occupational Cancer)","award":["25000.015000\/2019-53"],"award-info":[{"award-number":["25000.015000\/2019-53"]}]},{"name":"CNPq Productivity (Brazil) fellowship","award":["25000.015000\/2019-53"],"award-info":[{"award-number":["25000.015000\/2019-53"]}]},{"name":"PRONON\u2014PRONON\/MS (Abordagens m\u00f3veis e de tecnologia para preven\u00e7\u00e3o prim\u00e1ria e secund\u00e1ria de c\u00e2ncer\u2014NUP)","award":["25000.015000\/2019-53"],"award-info":[{"award-number":["25000.015000\/2019-53"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Lung cancer is the deadliest cancer worldwide. Tissue biopsy is currently employed for the diagnosis and molecular stratification of lung cancer. Liquid biopsy is a minimally invasive approach to determine biomarkers from body fluids, such as blood, urine, sputum, and saliva. Tumor cells release cfDNA, ctDNA, exosomes, miRNAs, circRNAs, CTCs, and DNA methylated fragments, among others, which can be successfully used as biomarkers for diagnosis, prognosis, and prediction of treatment response. Predictive biomarkers are well-established for managing lung cancer, and liquid biopsy options have emerged in the last few years. Currently, detecting EGFR p.(Tyr790Met) mutation in plasma samples from lung cancer patients has been used for predicting response and monitoring tyrosine kinase inhibitors (TKi)-treated patients with lung cancer. In addition, many efforts continue to bring more sensitive technologies to improve the detection of clinically relevant biomarkers for lung cancer. Moreover, liquid biopsy can dramatically decrease the turnaround time for laboratory reports, accelerating the beginning of treatment and improving the overall survival of lung cancer patients. Herein, we summarized all available and emerging approaches of liquid biopsy\u2014techniques, molecules, and sample type\u2014for lung cancer.<\/jats:p>","DOI":"10.3390\/ijms24032505","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T04:58:25Z","timestamp":1675054705000},"page":"2505","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5995-3808","authenticated-orcid":false,"given":"Giovanna Maria Stanfoca","family":"Casagrande","sequence":"first","affiliation":[{"name":"Molecular Oncology Research Center, Barretos Cancer Hospital, 1331 Rua Antenor Duarte Vilela, Barretos 14784-400, Brazil"}]},{"given":"Marcela de Oliveira","family":"Silva","sequence":"additional","affiliation":[{"name":"Molecular Oncology Research Center, Barretos Cancer Hospital, 1331 Rua Antenor Duarte Vilela, Barretos 14784-400, Brazil"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9639-7940","authenticated-orcid":false,"given":"Rui Manuel","family":"Reis","sequence":"additional","affiliation":[{"name":"Molecular Oncology Research Center, Barretos Cancer Hospital, 1331 Rua Antenor Duarte Vilela, Barretos 14784-400, Brazil"},{"name":"Life and Health Sciences Research Institute (ICVS), School of Medicine, Campus de Gualtar, University of Minho, 4710-057 Braga, Portugal"},{"name":"ICVS\/3B\u2019s\u2014PT Government Associate Laboratory, 4710-057 Braga, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2200-3985","authenticated-orcid":false,"given":"Let\u00edcia Ferro","family":"Leal","sequence":"additional","affiliation":[{"name":"Molecular Oncology Research Center, Barretos Cancer Hospital, 1331 Rua Antenor Duarte Vilela, Barretos 14784-400, Brazil"},{"name":"Barretos School of Medicine Dr. Paulo Prata\u2014FACISB, Barretos 14785-002, Brazil"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1158\/1078-0432.CCR-07-0317","article-title":"Survival of patients with clinical stage I lung cancer diagnosed by computed tomography screening for lung cancer","volume":"13","author":"Henschke","year":"2007","journal-title":"Clin. Cancer Res. AACR"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1200\/EDBK_158704","article-title":"Lung cancer screening, cancer treatment, and addressing the continuum of health risks caused by tobacco","volume":"36","author":"Warren","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_4","unstructured":"Howlader, N.N., Noone, A.M., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., and Lewis, D.R. (2020). SEER Cancer Statistics Review, 1975\u20132017."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7307","DOI":"10.1038\/sj.onc.1205807","article-title":"Tobacco use and cancer: An epidemiologic perspective for geneticists","volume":"21","author":"Thun","year":"2002","journal-title":"Oncogene"},{"key":"ref_6","unstructured":"Ridge, C.A., McErlean, A.M., and Ginsberg, M.S. (2013). Seminars in Interventional Radiology, Thieme Medical Publishers."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1164\/rccm.201302-0257OC","article-title":"Asbestos, Asbestosis, Smoking, and Lung Cancer. New Findings from the North American Insulator Cohort","volume":"188","author":"Markowitz","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.21037\/tlcr.2019.03.05","article-title":"Environmental and occupational determinants of lung cancer","volume":"8","author":"Shankar","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/ng.254","article-title":"Lung cancer susceptibility locus at 5p15.33","volume":"40","author":"McKay","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/ng.3892","article-title":"Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes","volume":"49","author":"McKay","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccm.2011.09.001","article-title":"Lung cancer: Epidemiology, etiology, and prevention","volume":"32","author":"Cruz","year":"2011","journal-title":"Clin. Chest Med."},{"key":"ref_13","unstructured":"Howlader, N.N.A.M., Noone, A.M., Krapcho, M.E., Miller, D., Brest, A., Yu, M.E., Ruhl, J., Tatalovich, Z., Mariotto, A., and Lewis, D.R. (2019). SEER Cancer Statistics Review, 1975\u20132016."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Duma, N., Santana-Davila, R., and Molina, J.R. (2019). Non\u2013Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment, Elsevier. Mayo Clinic Proceedings.","DOI":"10.1016\/j.mayocp.2019.01.013"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1038\/s41598-019-39965-x","article-title":"Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations","volume":"9","author":"Leal","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3892\/ol.2016.5518","article-title":"Familial risk for lung cancer","volume":"13","author":"Kanwal","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11912-022-01193-4","article-title":"Disparities in Lung Cancer Treatment","volume":"24","author":"Harrison","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Lim, M., Kim, C.-J., Sunkara, V., Kim, M.-H., and Cho, Y.-K. (2018). Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA). Micromachines, 9.","DOI":"10.3390\/mi9030100"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1533033818801809","DOI":"10.1177\/1533033818801809","article-title":"Liquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy","volume":"17","author":"Lu","year":"2018","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1159\/000492710","article-title":"Liquid Biopsy and Lung Cancer","volume":"63","author":"Pisapia","year":"2019","journal-title":"Acta Cytol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/bs.acc.2015.07.003","article-title":"Lung cancer biomarkers","volume":"72","author":"Hoseok","year":"2015","journal-title":"Adv. Clin. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/CCO.0000000000000267","article-title":"The potential of liquid biopsies","volume":"28","author":"Buder","year":"2016","journal-title":"Curr. Opin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Castro-Giner, F., Gkountela, S., Donato, C., Alborelli, I., Quagliata, L., Ng, C.K.Y., Piscuoglio, S., and Aceto, N. (2018). Cancer Diagnosis Using a Liquid Biopsy: Challenges and Expectations. Diagnostics, 8.","DOI":"10.3390\/diagnostics8020031"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: Towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11912-018-0720-z","article-title":"The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring","volume":"20","author":"Bracht","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2217\/lmt-2016-0006","article-title":"Liquid biopsy and NSCLC","volume":"5","author":"Trombetta","year":"2016","journal-title":"Lung Cancer Manag."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1373\/49.5.740","article-title":"Quantitative Analysis of Pleural Fluid Cell-free DNA as a Tool for the Classification of Pleural Effusions","volume":"49","author":"Chan","year":"2003","journal-title":"Clin. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/1759-7714.12350","article-title":"Evaluation of a novel saliva-based epidermal growth factor receptor mutation detection for lung cancer: A pilot study","volume":"7","author":"Pu","year":"2016","journal-title":"Thorac. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"9704","DOI":"10.1073\/pnas.1511694112","article-title":"Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord","volume":"112","author":"Wang","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1158\/1078-0432.CCR-16-2592","article-title":"Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced CancersKRAS Mutations in Urine cfDNA","volume":"23","author":"Fujii","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3816\/CLC.2006.n.043","article-title":"Cell-Free DNA Concentration in Pleural Fluid and Serum: Quantitative Approach and Potential Prognostic Factor in Patients with Cancer and Pleural Effusions","volume":"8","author":"Benlloch","year":"2006","journal-title":"Clin. Lung Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"key":"ref_35","unstructured":"Yamamoto, H., Watanabe, Y., and Itoh, F. (2019). Biomarkers in Cancer Therapy, Springer."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s43018-020-0043-5","article-title":"Circulating tumor DNA and liquid biopsy in oncology","volume":"1","author":"Cescon","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"28010","DOI":"10.1038\/srep28010","article-title":"Characterization of different CTC subpopulations in non-small cell lung cancer","volume":"6","author":"Hanssen","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_38","first-page":"42","article-title":"Circulating Tumor Cells and the Liquid Biopsy: Processed appropriately, liquid biopsy samples and circulating biomarkers may aid cancer diagnosis and predict treatment outcomes","volume":"39","author":"Shaffer","year":"2019","journal-title":"Genet. Eng. Biotechnol. News"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"55632","DOI":"10.18632\/oncotarget.17184","article-title":"Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer","volume":"8","author":"Jia","year":"2017","journal-title":"Oncotarget"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.mam.2018.07.003","article-title":"MicroRNA in lung cancer: Role, mechanisms, pathways and therapeutic relevance","volume":"70","author":"Iqbal","year":"2019","journal-title":"Mol. Asp. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/pcmedi\/pbz003","article-title":"Applying circulating tumor DNA methylation in the diagnosis of lung cancer","volume":"2","author":"Li","year":"2019","journal-title":"Precis. Clin. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1038\/s41467-018-07466-6","article-title":"Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease","volume":"9","author":"Moss","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"11981","DOI":"10.1002\/jcb.28482","article-title":"Integration of metabolomic and transcriptomic profiles to identify biomarkers in serum of lung cancer","volume":"120","author":"Sun","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.cca.2019.05.012","article-title":"Metabolomics workflow for lung cancer: Discovery of biomarkers","volume":"495","author":"Tang","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e1911970","DOI":"10.1001\/jamanetworkopen.2019.11970","article-title":"Association of Untargeted Urinary Metabolomics and Lung Cancer Risk Among Never-Smoking Women in China","volume":"2","author":"Seow","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_46","first-page":"992","article-title":"Lactate, choline, and creatine levels measured by vitro 1H-MRS as prognostic parameters in patients with non-small-cell lung cancer","volume":"25","author":"Yokota","year":"2007","journal-title":"J. Magn. Reson. Imaging Off. J. Int. Soc. Magn. Reson. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/annonc\/mdm007","article-title":"Autoantibodies in breast cancer: Their use as an aid to early diagnosis","volume":"18","author":"Chapman","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1111\/crj.12769","article-title":"Significance of tumor-associated autoantibodies in the early diagnosis of lung cancer","volume":"12","author":"Du","year":"2018","journal-title":"Clin. Respir. J."},{"key":"ref_49","first-page":"3911","article-title":"Applications of liquid biopsy in lung cancer-diagnosis, prognosis prediction, and disease monitoring","volume":"10","author":"Luo","year":"2018","journal-title":"Am. J. Transl. Res."},{"key":"ref_50","unstructured":"Miyanaga, A., Masuda, M., and Yamada, T. (2019). Biomarkers in Cancer Therapy, Springer."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: Genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_52","unstructured":"Davis, A.A., and Cristofanilli, M. (2019). Predictive Biomarkers in Oncology, Springer."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Gale, D., Lawson, A.R., Howarth, K., Madi, M., Durham, B., Smalley, S., Calaway, J., Blais, S., Jones, G., and Clark, J. (2018). Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0194630"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"349","DOI":"10.21037\/atm.2019.03.28","article-title":"Liquid biopsy for lung cancers: An update on recent developments","volume":"7","author":"Revelo","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Jee, J., Lebow, E.S., Murciano-Goroff, Y.R., Jayakumaran, G., Shen, R., Brannon, A.R., Benayed, R., Namakydoust, A., Offin, M., and Paik, P.K. (2021). Overall Survival with Circulating Tumor DNA-Guided Therapy in Advanced Non-Small Cell Lung Cancer, Wolters Kluwer Health.","DOI":"10.1200\/JCO.2021.39.15_suppl.9009"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/nbt1486","article-title":"Next-generation DNA sequencing","volume":"26","author":"Shendure","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Wong, W.H., Tong, R.S., Young, A.L., and Druley, T.E. (2018). Rare Event Detection Using Error-corrected DNA and RNA Sequencing. J. Vis. Exp., e57509.","DOI":"10.3791\/57509"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41525-018-0072-5","article-title":"TAC-seq: Targeted DNA and RNA sequencing for precise biomarker molecule counting","volume":"3","author":"Teder","year":"2018","journal-title":"NPJ Genom. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"66880","DOI":"10.18632\/oncotarget.11801","article-title":"Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer","volume":"7","author":"Villaflor","year":"2016","journal-title":"Oncotarget"},{"key":"ref_60","first-page":"575","article-title":"A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers","volume":"111","author":"Sabari","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_61","unstructured":"FuFaD, A. (2022, September 01). Aprova\u00e7\u00e3o Pr\u00e9-Comercializa\u00e7\u00e3o P150044, Teste de Muta\u00e7\u00e3o Cobas EGFR V2. 2017 FD, Available online: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf12\/p120019s007c.pdf."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/14737159.2020.1724094","article-title":"A profile on cobas\u00ae EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer","volume":"20","author":"Torres","year":"2020","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/15592294.2019.1695333","article-title":"DNA methylation biomarkers discovered in silico detect cancer in liquid biopsies from non-small cell lung cancer patients","volume":"15","author":"Vrba","year":"2020","journal-title":"Epigenetics"},{"key":"ref_64","unstructured":"Duruisseaux, M., and Esteller, M. (2018). Seminars in Cancer Biology, Elsevier."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.molonc.2015.10.021","article-title":"Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis","volume":"10","author":"Bjaanaes","year":"2016","journal-title":"Mol. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Wang, J., Duan, Y., Meng, Q.-H., Gong, R., Guo, C., Zhao, Y., and Zhang, Y. (2018). Integrated analysis of DNA methylation profiling and gene expression profiling identifies novel markers in lung cancer in Xuanwei, China. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0203155"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.1158\/1078-0432.CCR-17-1222","article-title":"A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non\u2013Small Cell Lung Cancer and Serum DNA","volume":"23","author":"Ooki","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"355","DOI":"10.17219\/acem\/84935","article-title":"DNA methylation analysis of selected genes for the detection of early-stage lung cancer using circulating cell-free DNA","volume":"28","author":"Yang","year":"2019","journal-title":"Adv. Clin. Exp. Med. Off. Organ Wroc. Med. Univ."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"517","DOI":"10.21037\/tlcr.2016.10.15","article-title":"Liquid biopsy in early stage lung cancer","volume":"5","author":"Robles","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1158\/1078-0432.CCR-16-1371","article-title":"Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and SputumEpigenetic Lung Cancer Screening","volume":"23","author":"Hulbert","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","article-title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","volume":"31","author":"Liu","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","article-title":"Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set","volume":"32","author":"Klein","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.3390\/cancers14194818","article-title":"Cell-Free DNA\u2013Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial","volume":"14","author":"Neal","year":"2022","journal-title":"Cancers"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.21037\/jtd.2020.02.24","article-title":"Possible role of circulating tumor cells in early detection of lung cancer","volume":"12","author":"Poggiana","year":"2020","journal-title":"J. Thorac. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/LCTT.S119644","article-title":"Osimertinib in the treatment of non-small-cell lung cancer: Design, development and place in therapy","volume":"8","author":"Santarpia","year":"2017","journal-title":"Lung Cancer Targets Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2147\/CMAR.S240773","article-title":"Circulating Tumor Cells as a Biomarker to Assist Molecular Diagnosis for Early Stage Non-Small Cell Lung Cancer","volume":"12","author":"He","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"7094","DOI":"10.18632\/oncotarget.12569","article-title":"Stem-like plasticity and heterogeneity of circulating tumor cells: Current status and prospect challenges in liver cancer","volume":"8","author":"Correnti","year":"2017","journal-title":"Oncotarget"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.2147\/IJN.S30593","article-title":"Detection of micrometastases in lung cancer with magnetic nanoparticles and quantum dots","volume":"7","author":"Zhang","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.lungcan.2015.09.008","article-title":"CellSearch\u00ae technology applied to the detection and quantification of tumor cells in CSF of patients with lung cancer leptomeningeal metastasis","volume":"90","author":"Tu","year":"2015","journal-title":"Lung Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2303.2010.00835.x","article-title":"Morphological analysis of circulating tumour cells in patients undergoing surgery for non-small cell lung carcinoma using the isolation by size of epithelial tumour cell (ISET) method","volume":"23","author":"Hofman","year":"2012","journal-title":"Cytopathology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/cancers10080270","article-title":"Assessment of the Mutational Status of NSCLC Using Hypermetabolic Circulating Tumor Cells","volume":"10","author":"Turetta","year":"2018","journal-title":"Cancers"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"S1373","DOI":"10.21037\/jtd.2017.10.67","article-title":"Exosomes as diagnostic and predictive biomarkers in lung cancer","volume":"9","author":"Reclusa","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.drudis.2017.03.004","article-title":"Exosomes: A new horizon in lung cancer","volume":"22","author":"Vanni","year":"2017","journal-title":"Drug Discov. Today"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1515\/hsz-2013-0141","article-title":"Current methods for the isolation of extracellular vesicles","volume":"394","author":"Balaj","year":"2013","journal-title":"Biol. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"23430","DOI":"10.3402\/jev.v3.23430","article-title":"Single-step isolation of extracellular vesicles by size-exclusion chromatography","volume":"3","author":"Grootemaat","year":"2014","journal-title":"J. Extracell. Vesicles"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3389\/fonc.2019.00931","article-title":"Double-Stranded DNA in Exosomes of Malignant Pleural Effusions as a Novel DNA Source for EGFR Mutation Detection in Lung Adenocarcinoma","volume":"9","author":"Qu","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_87","first-page":"531","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/gcc.22181","article-title":"Different exosome cargo from plasma\/bronchoalveolar lavage in non-small-cell lung cancer","volume":"53","author":"Silva","year":"2014","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3816\/CLC.2009.n.006","article-title":"Exosomal MicroRNA: A Diagnostic Marker for Lung Cancer","volume":"10","author":"Rabinowits","year":"2009","journal-title":"Clin. Lung Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1038\/emm.2016.153","article-title":"Exosome-derived microRNAs in cancer metabolism: Possible implications in cancer diagnostics and therapy","volume":"49","author":"Tomasetti","year":"2017","journal-title":"Exp. Mol. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3390\/cancers11060793","article-title":"Somatic Mutations in miRNA Genes in Lung Cancer\u2014Potential Functional Consequences of Non-Coding Sequence Variants","volume":"11","author":"Nawrocka","year":"2019","journal-title":"Cancers"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mrfmmm.2011.03.009","article-title":"MicroRNA history: Discovery, recent applications, and next frontiers","volume":"717","author":"Almeida","year":"2011","journal-title":"Mutat. Res.\/Fundam. Mol. Mech. Mutagen."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"10513","DOI":"10.1073\/pnas.0804549105","article-title":"Circulating microRNAs as stable blood-based markers for cancer detection","volume":"105","author":"Mitchell","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.ajpath.2012.01.034","article-title":"miR-143, miR-222, and miR-452 Are Useful as Tumor Stratification and Noninvasive Diagnostic Biomarkers for Bladder Cancer","volume":"180","author":"Jia","year":"2012","journal-title":"Am. J. Pathol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Zhi, F., Cao, X., Xie, X., Wang, B., Dong, W., Gu, W., Ling, Y., Wang, R., Yang, Y., and Liu, Y. (2013). Identification of Circulating MicroRNAs as Potential Biomarkers for Detecting Acute Myeloid Leukemia. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0056718"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Reis, P.P., Drigo, S.A., Carvalho, R.F., Lapa, R.M.L., Felix, T.F., Patel, D., Cheng, D., Pintilie, M., Liu, G., and Tsao, M.-S. (2020). Circulating miR-16-5p, miR-92a-3p, and miR-451a in Plasma from Lung Cancer Patients: Potential Application in Early Detection and a Regulatory Role in Tumorigenesis Pathways. Cancers, 12.","DOI":"10.3390\/cancers12082071"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Wozniak, M.B., Scelo, G., Muller, D.C., Mukeria, A., Zaridze, D., and Brennan, P. (2015). Circulating MicroRNAs as Non-Invasive Biomarkers for Early Detection of Non-Small-Cell Lung Cancer. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0125026"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"364316","DOI":"10.1155\/2014\/364316","article-title":"Deregulation of Serum MicroRNA Expression Is Associated with Cigarette Smoking and Lung Cancer","volume":"2014","author":"Huang","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.21037\/jtd.2017.09.01","article-title":"Circulating microRNA-34 family low expression correlates with poor prognosis in patients with non-small cell lung cancer","volume":"9","author":"Zhao","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"ref_100","unstructured":"Arnaiz, E., Sole, C., Manterola, L., Iparraguirre, L., Otaegui, D., and Lawrie, C.H. (2019). Seminars in Cancer Biology, Elsevier."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1093\/nar\/gkl151","article-title":"Characterization of RNase R-digested cellular RNA source that consists of lariat and circular RNAs from pre-mRNA splicing","volume":"34","author":"Suzuki","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"29769","DOI":"10.1074\/jbc.M606744200","article-title":"Substrate Recognition and Catalysis by the Exoribonuclease RNase R","volume":"281","author":"Vincent","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Salzman, J., Chen, R.E., Olsen, M.N., Wang, P.L., and Brown, P.O. (2013). Cell-type specific features of circular RNA expression. PLoS Genet., 9.","DOI":"10.1371\/annotation\/f782282b-eefa-4c8d-985c-b1484e845855"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nbt.2890","article-title":"Detecting and characterizing circular RNAs","volume":"32","author":"Jeck","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3389\/fgene.2019.00390","article-title":"Circular RNAs and RNA splice variants as biomarkers for prognosis and therapeutic response in the liquid biopsies of lung cancer patients","volume":"10","author":"Gazzeri","year":"2019","journal-title":"Front. Genet."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/1878-0261.13182","article-title":"Digital multiplexed analysis of circular RNAs in FFPE and fresh non-small cell lung cancer specimens","volume":"16","author":"Giannoukakos","year":"2022","journal-title":"Mol. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"31985","DOI":"10.1038\/srep31985","article-title":"Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1111\/febs.14132","article-title":"hsa_circ_0013958: A circular RNA and potential novel biomarker for lung adenocarcinoma","volume":"284","author":"Zhu","year":"2017","journal-title":"FEBS J."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3073467","DOI":"10.1155\/2018\/3073467","article-title":"The Circular RNA hsa_circ_0001445 Regulates the Proliferation and Migration of Hepatocellular Carcinoma and May Serve as a Diagnostic Biomarker","volume":"2018","author":"Zhang","year":"2018","journal-title":"Dis. Markers"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1002\/cam4.1514","article-title":"A novel plasma circular RNA circFARSA is a potential biomarker for non-small cell lung cancer","volume":"7","author":"Hang","year":"2018","journal-title":"Cancer Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"115774","DOI":"10.18632\/oncotarget.22404","article-title":"Next-generation metabolomics in lung cancer diagnosis, treatment and precision medicine: Mini review","volume":"8","author":"Yu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e1900042","DOI":"10.1002\/pmic.201900042","article-title":"Challenges and Opportunities in Cancer Metabolomics","volume":"19","author":"Kumar","year":"2019","journal-title":"Proteomics"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000074432","article-title":"Tumor Markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in Patients with Non-Small Cell Lung Cancer as an Aid in Histological Diagnosis and Prognosis","volume":"24","author":"Molina","year":"2003","journal-title":"Tumor Biol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.rmed.2003.11.003","article-title":"Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer","volume":"98","author":"Gimenez","year":"2004","journal-title":"Respir. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/172460081002500101","article-title":"Can the acute-phase reactant proteins be used as cancer biomarkers?","volume":"25","author":"Pang","year":"2010","journal-title":"Int. J. Biol. Markers"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1039\/c0mb00242a","article-title":"The Haptoglobin \u03b2 chain as a supportive biomarker for human lung cancers","volume":"7","author":"Kang","year":"2011","journal-title":"Mol. Biosyst."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1021\/pr101154j","article-title":"Identification and Validation of SAA as a Potential Lung Cancer Biomarker and its Involvement in Metastatic Pathogenesis of Lung Cancer","volume":"10","author":"Sung","year":"2011","journal-title":"J. Proteome Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1042\/bj3340489","article-title":"Regulation of serum amyloid A protein expression during the acute-phase response","volume":"334","author":"Jensen","year":"1998","journal-title":"Biochem. J."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.lungcan.2008.06.003","article-title":"Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer","volume":"63","author":"Orre","year":"2009","journal-title":"Lung Cancer"},{"key":"ref_120","first-page":"61","article-title":"Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer","volume":"53","author":"Pujol","year":"1993","journal-title":"Cancer Res."},{"key":"ref_121","first-page":"1833","article-title":"Cytokeratin 8 and 18 fragments measured in serum and their relation to survival in patients with non-small cell lung cancer","volume":"19","author":"Bergqvist","year":"1999","journal-title":"Anticancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/prca.200800094","article-title":"MALDI-MS derived prognostic protein markers for resected non-small cell lung cancer","volume":"2","author":"Xu","year":"2008","journal-title":"Proteom. Clin. Appl."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Zamay, T.N., Zamay, G.S., Kolovskaya, O.S., Zukov, R.A., Petrova, M.M., Gargaun, A., Berezovski, M.V., and Kichkailo, A.S. (2017). Current and Prospective Protein Biomarkers of Lung Cancer. Cancers, 9.","DOI":"10.3390\/cancers9110155"},{"key":"ref_125","unstructured":"Alcala, K., Guida, F., Johansson, M., Johansson, M., Robbins, H.A., Smith-Byrne, K., Stevens, V., and Zahed, H. (2022). Lung Cancer Cohort Consortium The Blood Proteome of Imminent Lung Cancer Diagnosis. medRxiv."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1559-0275-11-32","article-title":"Validation of a blood protein signature for non-small cell lung cancer","volume":"11","author":"Mehan","year":"2014","journal-title":"Clin. Proteom."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/annonc\/mdq361","article-title":"Clinical validation of an autoantibody test for lung cancer","volume":"22","author":"Boyle","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1172\/JCI14451","article-title":"Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis","volume":"108","author":"Tan","year":"2001","journal-title":"J. Clin. Investig."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1084\/jem.180.1.1","article-title":"Cancer antigens: Immune recognition of self and altered self","volume":"180","author":"Houghton","year":"1994","journal-title":"J. Exp. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1600-065X.2008.00611.x","article-title":"Autoantibodies to tumor-associated antigens: Reporters from the immune system","volume":"222","author":"Tan","year":"2008","journal-title":"Immunol. Rev."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1586\/erm.10.12","article-title":"Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors","volume":"10","author":"Zhang","year":"2010","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2217\/bmm.15.122","article-title":"The challenge of small lung nodules identified in CT screening: Can biomarkers assist diagnosis?","volume":"10","author":"Veronesi","year":"2016","journal-title":"Biomark. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.lungcan.2016.07.018","article-title":"Autoantibodies against tumor-associated antigens in the early detection of lung cancer","volume":"99","author":"Dai","year":"2016","journal-title":"Lung Cancer"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1097\/JTO.0000000000000302","article-title":"Biomarkers in Early-Stage Non\u2013Small-Cell Lung Cancer: Current Concepts and Future Directions","volume":"9","author":"Burotto","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.canlet.2014.01.007","article-title":"Blood autoantibodies against tumor-associated antigens as biomarkers in early detection of colorectal cancer","volume":"346","author":"Chen","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nm0795-701","article-title":"Serum p53 antibodies as early markers of lung cancer","volume":"1","author":"Lubin","year":"1995","journal-title":"Nat. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1093\/annonc\/mdp606","article-title":"Technical validation of an autoantibody test for lung cancer","volume":"21","author":"Murray","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1158\/1078-0432.CCR-09-3192","article-title":"Development of a Multiplexed Tumor-Associated Autoantibody-Based Blood Test for the Detection of Non\u2013Small Cell Lung CancerEarly Detection Serum Test for NSCLC","volume":"16","author":"Farlow","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1158\/1078-0432.CCR-10-0193","article-title":"Development of Autoantibody Signatures as Novel Diagnostic Biomarkers of Non\u2013Small Cell Lung CancerNew Serum Diagnostic Biomarkers for NSCLC","volume":"16","author":"Wu","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1158\/1940-6207.CAPR-10-0328","article-title":"EarlyCDT-Lung: An Immunobiomarker Test as an Aid to Early Detection of Lung Cancer","volume":"4","author":"Lam","year":"2011","journal-title":"Cancer Prev. Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"108262","DOI":"10.1016\/j.clim.2019.108262","article-title":"Screening of tumor-associated antigens based on Oncomine database and evaluation of diagnostic value of autoantibodies in lung cancer","volume":"210","author":"Wang","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"151848","DOI":"10.1016\/j.imbio.2019.09.007","article-title":"A panel of autoantibodies against tumor-associated antigens in the early immunodiagnosis of lung cancer","volume":"225","author":"Jiang","year":"2020","journal-title":"Immunobiology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1097\/CM9.0000000000001097","article-title":"Circulating tumor DNA in lung cancer: Real-time monitoring of disease evolution and treatment response","volume":"133","author":"Li","year":"2020","journal-title":"Chin. Med. J."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/resp.12696","article-title":"Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non-small-cell lung cancer","volume":"21","author":"Zhang","year":"2016","journal-title":"Respirology"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1200\/JCO.2010.33.3716","article-title":"Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer","volume":"30","author":"Hou","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1111\/1759-7714.13219","article-title":"Presence of mEGFR ctDNA predicts a poor clinical outcome in lung adenocarcinoma","volume":"10","author":"Kim","year":"2019","journal-title":"Thorac. Cancer"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.21037\/tlcr.2019.12.16","article-title":"Extracellular vesicle-based EGFR genotyping in bronchoalveolar lavage fluid from treatment-naive non-small cell lung cancer patients","volume":"8","author":"Hur","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Michaelidou, K., Koutoulaki, C., Mavridis, K., Vorrias, E., Papadaki, M.A., Koutsopoulos, A.V., Mavroudis, D., and Agelaki, S. (2020). Detection of KRAS G12\/G13 Mutations in Cell Free-DNA by Droplet Digital PCR, Offers Prognostic Information for Patients with Advanced Non-Small Cell Lung Cancer. Cells, 9.","DOI":"10.3390\/cells9112514"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"855","DOI":"10.21037\/tlcr-20-826","article-title":"The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer","volume":"10","author":"Wen","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"202","DOI":"10.21037\/tlcr-20-674","article-title":"Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: Impact of STK11, KRAS and TP53 mutations and co-mutations on outcome","volume":"10","author":"Pavan","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s00595-009-4094-6","article-title":"Aberrant methylation in non-small cell lung cancer","volume":"40","author":"Suzuki","year":"2010","journal-title":"Surg. Today"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMoa0706550","article-title":"DNA Methylation Markers and Early Recurrence in Stage I Lung Cancer","volume":"358","author":"Brock","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/cas.14199","article-title":"Circulating micro RNA-590-5p functions as a liquid biopsy marker in non-small cell lung cancer","volume":"111","author":"Khandelwal","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1073\/pnas.1100048108","article-title":"MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer","volume":"108","author":"Boeri","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.gene.2016.06.014","article-title":"Aberrant miR-181b-5p and miR-486-5p expression in serum and tissue of non-small cell lung cancer","volume":"591","author":"Tian","year":"2016","journal-title":"Gene"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/jso.22008","article-title":"Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer","volume":"104","author":"Wang","year":"2011","journal-title":"J. Surg. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Bianconi, F., Palumbo, I., Spanu, A., Nuvoli, S., Fravolini, M.L., and Palumbo, B. (2020). PET\/CT Radiomics in Lung Cancer: An Overview. Appl. Sci., 10.","DOI":"10.3390\/app10051718"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00595-018-1659-2","article-title":"A liquid biopsy in primary lung cancer","volume":"49","author":"Yoneda","year":"2019","journal-title":"Surg. Today"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.trecan.2018.07.004","article-title":"Improving Cancer Detection and Treatment with Liquid Biopsies and ptDNA","volume":"4","author":"Kessler","year":"2018","journal-title":"Trends Cancer"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/cncr.28964","article-title":"Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non\u2013small cell lung cancer during treatment with erlotinib","volume":"120","author":"Sorensen","year":"2014","journal-title":"Cancer"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"v577","DOI":"10.1093\/annonc\/mdz257.010","article-title":"Feasibility study of a ctEGFR prototype assay on the fully automated Idylla\u2122 platform","volume":"30","author":"Reijans","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cllc.2019.07.010","article-title":"Critical Assessment in Routine Clinical Practice of Liquid Biopsy for EGFR Status Testing in Non\u2013Small-Cell Lung Cancer: A Single-Laboratory Experience (LPCE, Nice, France)","volume":"21","author":"Heeke","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.02.001","article-title":"Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures","volume":"174","author":"Lee","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3747\/co.25.3761","article-title":"Circulating Tumour DNA in EGFR-Mutant Non-Small-Cell Lung Cancer","volume":"25","author":"Cabanero","year":"2018","journal-title":"Curr. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.lungcan.2019.06.021","article-title":"The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study","volume":"134","author":"Ding","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"488","DOI":"10.18632\/oncotarget.22470","article-title":"Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients","volume":"9","author":"Provencio","year":"2018","journal-title":"Oncotarget"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"461","DOI":"10.17554\/j.issn.1819-6187.2016.04.95","article-title":"Clinical and Investigational Applications of Liquid Biopsy in Non-Small Cell Lung Cancer","volume":"4","author":"Torrente","year":"2016","journal-title":"J. Tumor"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"31726","DOI":"10.1038\/srep31726","article-title":"Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab","volume":"6","author":"Nicolazzo","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1158\/1055-9965.EPI-17-0120","article-title":"Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival","volume":"26","author":"Boffa","year":"2017","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/annonc\/mdx636","article-title":"Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer","volume":"29","author":"Hofman","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse CancersTMB Predicts Response to Immunotherapy in Diverse Cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/jama.2019.3241","article-title":"Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non\u2013Small Cell Lung Cancer Using a Clinicogenomic Database","volume":"321","author":"Singal","year":"2019","journal-title":"JAMA"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","article-title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","volume":"24","author":"Gandara","year":"2018","journal-title":"Nat. Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1158\/1078-0432.CCR-17-3837","article-title":"The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer PatientsSomatic Genomic Landscape of Circulating Tumor DNA","volume":"24","author":"Zill","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical Features and Outcome of Patients With Non\u2013Small-Cell Lung Cancer Who Harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.18632\/oncotarget.6279","article-title":"Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer","volume":"7","author":"Nilsson","year":"2016","journal-title":"Oncotarget"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1911793","article-title":"Reduced lung-cancer mortality with volume CT screening in a randomized trial","volume":"382","author":"Scholten","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"e2100257","DOI":"10.1200\/GO.21.00257","article-title":"Challenges of Implementing Lung Cancer Screening in a Developing Country: Results of the Second Brazilian Early Lung Cancer Screening Trial (BRELT2)","volume":"8","author":"Hochhegger","year":"2022","journal-title":"JCO Glob. Oncol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"10732748221121385","DOI":"10.1177\/10732748221121385","article-title":"Implementation of an Integrated Lung Cancer Prevention and Screening Program Using a Mobile Computed Tomography (CT) Unit in Brazil","volume":"29","author":"Chiarantano","year":"2022","journal-title":"Cancer Control"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"170070","DOI":"10.1098\/rsob.170070","article-title":"Progress and prospects of early detection in lung cancer","volume":"7","author":"Crosbie","year":"2017","journal-title":"Open Biol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"eaan2415","DOI":"10.1126\/scitranslmed.aan2415","article-title":"Direct detection of early-stage cancers using circulating tumor DNA","volume":"9","author":"Phallen","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3389\/fonc.2015.00209","article-title":"Current status of CTCs as liquid biopsy in lung cancer and future directions","volume":"5","author":"Zhang","year":"2015","journal-title":"Front. Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/JTO.0b013e318208c785","article-title":"miR-1254 and miR-574-5p: Serum-Based microRNA Biomarkers for Early-Stage Non-small Cell Lung Cancer","volume":"6","author":"Foss","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.annonc.2022.01.008","article-title":"Baseline computed tomography screening and blood microRNA predict lung cancer risk and define adequate intervals in the BioMILD trial","volume":"33","author":"Pastorino","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Kumar, S., Gaur, V., Mir, I.A., Saikia, J., and Kumar, S. (2022). MicroRNA-3692-3p is overexpressed in lung tumors but may not serve as a prognostic biomarker in lung cancer patients. Mol. Biol. Rep., 1\u201310.","DOI":"10.1007\/s11033-022-08119-0"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.2147\/IJGM.S367999","article-title":"Circular RNAs Hsa_circ_101555 and Hsa_circ_008068 as Diagnostic Biomarkers for Early-Stage Lung Adenocarcinoma","volume":"15","author":"Lian","year":"2022","journal-title":"Int. J. Gen. Med."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Zhang, Q., Qin, S., Peng, C., Liu, Y., Huang, Y., and Ju, S. (2022). Circulating circular RNA hsa_circ_0023179 acts as a diagnostic biomarker for non-small-cell lung cancer detection. J. Cancer Res. Clin. Oncol., 1\u201312.","DOI":"10.1007\/s00432-022-04254-0"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.annepidem.2022.10.014","article-title":"Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program","volume":"77","author":"Robbins","year":"2023","journal-title":"Ann. Epidemiol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"eabb9601","DOI":"10.1126\/science.abb9601","article-title":"Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention","volume":"369","author":"Lennon","year":"2020","journal-title":"Science"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"e200409","DOI":"10.1001\/jamanetworkopen.2020.0409","article-title":"Assessment of Biomarker Testing for Lung Cancer Screening Eligibility","volume":"3","author":"LaRose","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.jtho.2022.08.011","article-title":"Stage Migration and Lung Cancer Incidence After Initiation of Low-Dose Computed Tomography Screening","volume":"17","author":"Vachani","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s41591-021-01672-4","article-title":"A roadmap to increase diversity in genomic studies","volume":"28","author":"Fatumo","year":"2022","journal-title":"Nat. Med."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.ccell.2021.04.013","article-title":"Precision oncology: Directing genomics and pharmacogenomics toward reducing cancer inequities","volume":"39","author":"Saulsberry","year":"2021","journal-title":"Cancer Cell"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/3\/2505\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:17:38Z","timestamp":1760120258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/3\/2505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,28]]},"references-count":194,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24032505"],"URL":"https:\/\/doi.org\/10.3390\/ijms24032505","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,28]]}}}